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 Abstract: The signifi cant increase in pediatric-onset 
infl ammatory bowel disease in recent decades 
appears to be a global phenomenon, with studies 
from multiple geographic areas noting an increase 
in Crohn’s disease (CD) and ulcerative colitis 
(UC). In this large, population-based cohort from 
northern France, the rapid increase in pediatric CD 
and UC from 1988–2011 may be due to multiple 
potential etiologies including environmental factors 
and advancements in diagnostic capabilities. We 
should consider the clinical implications of this rise 
in incidence, including potential risk stratifi cation 
approaches that may offer the ability to modify the 
disease course of patients with earlier diagnosis.
 Am J Gastroenterol 2018; 113:273–275; doi: 10.1038/ajg.2017.431 
 Pediatric-onset infl ammatory bowel disease (IBD) has signifi -
cantly increased in incidence and prevalence in recent decades, 
with these shift s occurring in both developing and developed 
nations ( 1 ). Indeed, this appears to be a global phenomenon with 
studies from multiple geographic areas documenting an increas-
ing incidence of pediatric Crohn’s disease (CD) and ulcerative 
colitis (UC) ( 2–7 ). Despite recognition that these trends exist, the 
defi nitive explanations for such trends have not been established 
to this point. In addition, comparisons across studies have been 
diffi  cult due to the heterogeneity in study design, data collections, 
and populations surveyed.
 In this issue of  Th e American Journal of Gastroenterology , 
Ghione  et al. ( 8 ) describe a signifi cant increase in the incidence 
of UC and CD in a large, population-based cohort from northern 
France. Th e source population for this study represents approxi-
mately 9% of the French population, and data regarding diagnoses 
of patients with IBD are collected from every adult and pediatric 
gastroenterology practice in the included geographic area. Inci-
dence rates were computed, and divided into 3-year periods 
throughout the entire study period (1988–2011). Th e mean 
annual incidence rates were then calculated for the entire study 
period and for each 3-year interval period.
 From 1988 to 2011, the authors noted a signifi cant rise in both 
CD (from 2.1 to 4.7 per 100,000) and UC (0.8 to 2.1 per 100,000), 
whereas the incidence of IBD-undiff erentiated remained stable. 
Th e fi ndings among adolescents were particularly striking, with 
the overall incidence of IBD signifi cantly increasing from 6.0 
to 13.8 per 100,000. Among adolescents, the incidence of CD 
demonstrated an average yearly change of +4.3%. Th e incidence 
of UC among adolescents remained stable until 1999 and then 
demonstrated a dramatic increase from 2000 to 2011, with an 
average yearly change of over 11%.
 Th e major strength of the study lies in the ability to study a large 
population over a period of 24 years, allowing for the identifi ca-
tion of ~8% of all incident cases of pediatric IBD in France during 
the study period. Th is ability to perform population level analy-
sis while maintaining granularity of clinical data for individual 
patients off ers a unique opportunity for epidemiologic research. 
Th e fi nal diagnosis of CD or UC was established by expert gastro-
enterologists, which adds further validity to the study design.
 Th e striking increase in incidence of IBD among pediatric 
patients in this cohort from northern France is consistent with 
fi ndings in other cohorts from other areas of the world ( 2–7,9 ). 
In a recent issue of  Th e American Journal of Gastroenterology , 
Benchimol  et al. ( 9 ) utilized provincial health administrative data-
bases to study national trends in the epidemiology of pediatric 
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increase in awareness of the signs/symptoms of IBD among pedi-
atric patients during the 24-year study period. Th ese diagnostic 
advances include, but are not limited to increased use of cross sec-
tional imaging, capsule endoscopy, and laboratory markers such 
as fecal calprotectin. If some of the apparent increase in the inci-
dence of pediatric IBD is due to earlier diagnosis, this should be 
applauded, as diagnostic delay has been a noted problem among 
patients with CD and UC ( 20 ).
 Th e authors note that if improved diagnostics were the expla-
nation for increasing incidence in the early to middle years of 
this study, incidence rates would have plateaued or possibly 
even declined in the later years of this study. Th is was not the 
case. Although a steady increase in incidence of CD was noted 
throughout the study period, the increase in UC was later. We 
speculate that improved access to care and advances in diagnos-
tics improved over the entire course of this study and continue to 
evolve today. Th erefore, incidence rates may not have “peaked” 
to this point. It will be interesting to continue to follow this 
population to see if the increases in incidence of CD and UC are 
sustained or if a plateau does in fact occur in the future.
 We should also consider the clinical implications of these 
fi ndings. On the one hand, it is possible that we may be detect-
ing more mild patients (infl ammatory CD or left -sided UC or 
proctitis) and perhaps a subset of these patients may not require 
lifelong immunosuppressive therapy at the time of diagnosis. 
On the other hand, perhaps we are detecting patients earlier in 
the course of disease, prior to the development of fi brostenotic, 
internal penetrating disease, and other complications. Perhaps 
there is a critical window in which early, aggressive therapy may 
be particularly impactful in altering the natural history of disease 
in such patients. Th ese scenarios point to the urgent need for 
better prognostic markers and risk stratifi cation tools, so that we 
can better identify the subset of patients who will benefi t from 
early, aggressive therapy, and the subset for whom a “watch and 
wait” approach is most appropriate. New strategies such as those 
emerging from a recent multicenter inception cohort study of 
pediatric patients with IBD ( 21 ) will be critical to understanding 
the natural history of IBD among pediatric patients and guiding 
therapy choices in this population.
 In conclusion, Ghione  et al. ( 8 ) present a provocative study 
detailing a rapidly increasing incidence of CD and UC among 
pediatric patients in northern France. Th eir use of a prospective, 
population-based registry allows for a unique analysis of the epi-
demiologic patterns of IBD in this region over a 24-year study 
period. Th ese fi ndings, when placed alongside similar reports of 
an increasing incidence of IBD among pediatric patients world-
wide, should spark further interest into the drivers of these epide-
miologic trends and the prognostic and therapeutic implications 
if children are being diagnosed earlier in their disease and prior to 
the development of structuring/penetrating complications.
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IBD in Canada. Th ese investigators described a marked incidence 
of very early onset IBD along with a more modest and not sta-
tistically signifi cant increase in the overall incidence of pediatric 
IBD [annual percentage change +2.06% (95% confi dence interval 
−0.64% to +4.76%)] ( 9 ). Although the age groups impacted were
somewhat diff erent between the Canadian and French studies,
taken together, these and other studies raise multiple questions
surrounding the potential drivers of these apparent increases
in the incidence of pediatric IBD. We must fi rst realize that the
increased incidence demonstrated in this study (and others)
occurs over too short of a time period to represent genetic shift s in
populations. Th us, the increasing incidence of IBD is likely driven 
by environmental infl uences ( 10 ), including the hygiene hypothe-
sis ( 11 ), the association between antibiotic exposure in childhood
and increased risk of development of IBD ( 12–14 ), and appendec-
tomy ( 15,16 ). In the present study, Ghione  et al. ( 8 ) review many 
of these factors, and include an excellent discussion of temporal
trends of antibiotic prescription patterns and utilization of appen-
dectomy in France during the study period.
  Indirect support for environmental factors in the pathogenesis 
of IBD comes from studies of immigrant populations, where con-
sistent evidence has demonstrated an increased risk of develop-
ing IBD among immigrants moving from a low prevalence area 
to a high prevalence area ( 17,18 ). Although many environmen-
tal factors have been associated with an increased risk of CD and 
UC, we should also consider that currently unidentifi ed environ-
mental risk factors that increase an individual’s risk of develop-
ing IBD may also exist. Although the increase in the incidence of 
pediatric IBD demonstrated in the study by Ghione  et al. ( 8 ) is 
striking, France has traditionally been viewed as a region of high 
IBD prevalence. Perhaps more impressive is the rising incidence 
of IBD in previously low incidence areas such as Asia ( 19 ). Future 
studies aimed at the identifi cation of novel environmental triggers 
in each of these geographic areas has the potential to signifi cantly 
impact our understanding of the pathophysiology of IBD, poten-
tially leading to new methods to diagnose, risk stratify, or treat 
patients with CD and UC.
  We should also consider whether the rising incidence of pedi-
atric IBD may refl ect an increased ability to diagnose CD and UC 
among children, and to make this diagnosis earlier in the disease 
course. Th i s c oncept i s s upported b y t he s tudy’s fi nd ing of  an  
increase in the percentage of patients with B1 (infl ammatory) dis-
ease, which increased from 64% during the period from 1988 to 
1990 to 87% during the period from 2009 to 2011 ( P <0.001). Th i s 
was accompanied by a signifi cant decrease in B2 (stricturing) dis-
ease (33 to 11%). Traditionally, B1 disease has been viewed as an 
“earlier” phenotype of CD, with the potential to progress to more 
advanced phenotypes such as B2 and B3 (penetrating) disease 
over time. Improved and/or earlier diagnosis of pediatric IBD 
may be attributed to improved access to subspecialty care and/or 
more advanced diagnostic tools. In the population from France 
included in this study, the number of pediatric gastroenterolo-
gists increased from 3 in 1988 to 15 (currently). Th is increase in 
access to care by a pediatric gastroenterologist was also accompa-
nied by major advances in our diagnostic capabilities and a 
likely 
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